Differential Expression of O-glycoprotein Glycans in Cholangiocarcinoma Cell Lines

  • Talabnin, Krajang (School of Pathology, Institute of Medicine, Suranaree University of Technology) ;
  • Talabnin, Chutima (School of Biochemistry, Institute of Science, Suranaree University of Technology) ;
  • Ishihara, Mayumi (Complex Carbohydrate Research Center, The University of Georgia) ;
  • Azadi, Parastoo (Complex Carbohydrate Research Center, The University of Georgia) ;
  • Wongkham, Sopit (Department of Biochemistry, Faculty of Medicine, Khon Kaen University) ;
  • Sripa, Banchob (Department of Pathology, Faculty of Medicine, Khon Kaen University)
  • Published : 2016.03.07


Protein glycosylation is the most common posttranslational modification in mammalian cells. Aberrant protein glycosylation has been reported in various diseases, including cancer. We identified and quantified the glycan structures of O-linked glycoprotein from cholangiocarcinoma (CCA) cell lines from different histological types and compared their profiles by nanospray ionization-linear ion trap mass spectrometry (NSI-$MS^n$). Five human CCA cell lines, K100, M055, M139, M213 and M214 were characterized. The results showed that the O-linked glycans of the CCA cell lines comprised tri- to hexa-saccharides with terminal galactose and sialic acids: NeuAc1Gal1GalNAc1, Gal2GlcNAc1GalNAc1, NeuAc2Gal1GalNAc1 NeuAc1Gal2GlcNAc1GalNAc1 and NeuAc2Gal2GlcNAc1GalNAc1 All five CCA cell lines showed a similar glycan pattern, but with differences in their quantities. NeuAc1Gal1GalNAc1 proved to be the most abundant structure in poorly differentiated adenocarcinoma (K100; 57.1%), moderately differentiated adenocarcinoma (M055; 42.6%) and squamous cell carcinoma (M139; 43.0%), while moderately to poorly differentiated adenocarcinoma (M214; 40.1%) and adenosquamous cell carcinoma (M213; 34.7%) appeared dominated by $NeuA_{c2}Gal_1GalNA_{c1}$. These results demonstrate differential expression of the O-linked glycans in the different histological types of CCA. All five CCA cell lines have abundant terminal sialic acid (NeuAc) O-linked glycans, suggesting an important role for sialic acid in cancer cells. Our structural analyses of glycans may provide important information regarding physiology of disease-related glycoproteins in CCA.


Cholangiocarcinoma;glycoprotein;O-linked glycans;sialic acid


Supported by : Office of the Higher Education Commission (OHEC), Thailand Research Fund (TRF), Mahasarakham University


  1. Anumula KR, Taylor PB (1992). A comprehensive procedure for preparation of partially methylated alditol acetates from glycoprotein carbohydrates. Anal Biochem, 203, 101-8.
  2. Aoki K, Perlman M, Lim JM, et al (2007). Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo. J Biol Chem, 282, 9127-42.
  3. Aoki K, Porterfield M, Lee SS, et al (2008). The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem, 283, 30385-400.
  4. Apweiler R, Hermjakob H, Sharon N (1999). On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochimica Et Biophysica Acta, 1473, 4-8.
  5. Brockhausen I, Yang JM, Burchell J, et al (1995). Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem, 233, 607-17.
  6. Bull C, Stoel MA, den Brok MH, et al (2014). Sialic acids sweeten a tumor's life. Cancer Res, 74, 3199-204.
  7. Burchell J, Poulsom R, Hanby A, et al (1999). An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiol, 9, 1307-11.
  8. Chik JH, Zhou J, Moh ES, et al (2014). Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies. J Proteomics, 108, 146-62.
  9. Domon B, Costello CE (1988). Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. Biochemistry, 27, 1534-43.
  10. Indramanee S, Silsirivanit A, Pairojkul C, et al (2012). Aberrant glycosylation in cholangiocarcinoma demonstrated by lectinhistochemistry. Asian Pac J Cancer Prev, 13, 119-24.
  11. Juntavee A, Sripa B, Pugkhem A, et al (2005). Expression of sialyl Lewis(a) relates to poor prognosis in cholangiocarcinoma. World J Gastroenterol, 11, 249-54.
  12. Kim EH, Misek DE (2011). Glycoproteomics-based identification of cancer biomarkers. Int J Proteomics, 2011, 601937.
  13. Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatol, 33, 1353-7.
  14. Phoomak C, Silsirivanit A, Wongkham C, et al (2012). Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Asian Pac J Cancer Prev, 13, 101-5.
  15. Sawanyawisuth K, Silsirivanit A, Kunlabut K, et al (2012). A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis. Parasitology Int, 61, 151-4.
  16. Shaib YH, Davila JA, McGlynn K, et al (2004). Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol, 40, 472-7.
  17. Silsirivanit A, Araki N, Wongkham C, et al (2011). A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer, 117, 3393-403.
  18. Silsirivanit A, Araki N, Wongkham C, et al (2013). CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci, 104, 1278-84.
  19. Wong CH (2005). Protein glycosylation: new challenges and opportunities. J Organic Chemistry, 70, 4219-25.

Cited by

  1. Mass spectrometry for protein sialoglycosylation pp.02777037, 2017,